当前位置:首页 - 行情中心 - 威尔药业(603351) - 财务分析 - 利润表

威尔药业

(603351)

  

流通市值:38.03亿  总市值:38.03亿
流通股本:1.35亿   总股本:1.35亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入673,722,955.67349,725,188.551,296,753,389.061,000,364,429.23
  营业收入673,722,955.67349,725,188.551,296,753,389.061,000,364,429.23
二、营业总成本588,979,381.47307,861,914.391,137,417,233.03886,687,537.69
  营业成本484,557,044.44258,644,574.16929,479,269.55741,019,493.32
  税金及附加4,373,876.452,194,359.968,701,785.76,702,957.05
  销售费用7,317,179.473,064,721.6914,471,230.0110,424,902.41
  管理费用48,425,467.7522,880,583.92101,371,471.5771,277,490.08
  研发费用38,837,337.1118,198,856.6171,561,298.6347,691,176.39
  财务费用5,468,476.252,878,818.0511,832,177.579,571,518.44
  其中:利息费用5,955,785.212,921,468.8413,837,458.6610,548,555.71
  其中:利息收入176,372.05144,450.19925,452.55746,897.77
三、其他经营收益
  加:公允价值变动收益1,736.22-12,072,961.1312,072,961.13
  加:投资收益---68,939.98-68,940
  资产处置收益6,484.576,484.57--
  资产减值损失(新)-2,467,637.19--9,014,547.81-3,847,764.11
  信用减值损失(新)-449,956.84-219,574.21-357,076.34-83,519.23
  其他收益4,116,917.551,369,147.8410,381,884.367,148,520.41
四、营业利润85,951,118.5143,019,332.36172,350,437.39128,898,149.74
  减:营业外支出94,473.0269,616.87219,173.52167,145.27
五、利润总额85,856,645.4942,949,715.49172,131,263.87128,731,004.47
  减:所得税费用14,554,015.037,183,536.9526,925,425.1717,699,818.17
六、净利润71,302,630.4635,766,178.54145,205,838.7111,031,186.3
(一)按经营持续性分类
  持续经营净利润71,302,630.4635,766,178.54145,205,838.7111,031,186.3
(二)按所有权归属分类
  归属于母公司股东的净利润72,766,854.5236,587,563.15146,421,823.99112,897,296.64
  少数股东损益-1,464,224.06-821,384.61-1,215,985.29-1,866,110.34
  扣除非经常损益后的净利润72,248,911.4936,375,002.98135,856,039.41103,272,501.91
七、每股收益
  (一)基本每股收益0.540.271.080.83
  (二)稀释每股收益0.540.271.080.83
九、综合收益总额71,302,630.4635,766,178.54145,205,838.7111,031,186.3
  归属于母公司股东的综合收益总额72,766,854.5236,587,563.15146,421,823.99112,897,296.64
  归属于少数股东的综合收益总额-1,464,224.06-821,384.61-1,215,985.29-1,866,110.34
公告日期2025-08-202025-04-222025-04-222024-10-24
审计意见(境内)标准无保留意见
TOP↑